inclusion criteria: - patients between 18 and 70 years old - covid-19+ patients diagnosed upon biological testing (pcr coronavirus sars-cov2) - hospitalized patients - obese individuals (bmi≥30kg/m²) - lymphocyte counts between 500 and 1500/mm3. - patients upon oxygen (either using mask or nasal cannula). - patients within their first 7 days after the beginning of symptoms. - women of childbearing potential: effective contraception for the duration of the study and 5 months after the administration of treatment. - patient who understands and accepts the need for a long term follow-up, - patients who agrees to be included in the study and who signs the informed consent form, - patients affiliated to a healthcare insurance plan.

inclusion criteria: - patients between 18 and 70 years old - covid-19+ patients diagnosed upon biological testing (pcr coronavirus sars-cov2) - hospitalized patients - obese individuals (bmi≥30kg/m²) - lymphocyte counts between 500 and 1500/mm3. - patients upon oxygen (either using mask or nasal cannula). - patients within their first 7 days after the beginning of symptoms. - women of childbearing potential: effective contraception for the duration of the study and 5 months after the administration of treatment. - patient who understands and accepts the need for a long term follow-up, - patients who agrees to be included in the study and who signs the informed consent form, - patients affiliated to a healthcare insurance plan.